Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology
  • Published:

Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis – JCOG study 9413

Abstract

Thirty-three patients with lung cancer receiving 80 mg m(-2) cisplatin were treated with high-dose dexamethasone (32 mg m(-2) on days 1-3, 16 mg m(-2) on day 4 and 8 mg m(-2) on day 5) combined with granisetron on day 1 and metoclopramide on days 2-5. Twenty-eight (85%) patients had no nausea or vomiting on day 1, and 16 (48%) achieved total control on days 1-5 with acceptable toxicity. High-dose dexamethasone for cisplatin-induced delayed emesis should be further evaluated in a phase III trial.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sekine, I., Nishiwaki, Y., Kakinuma, R. et al. Phase II study of high-dose dexamethasone-based association in acute and delayed high-dose cisplatin-induced emesis – JCOG study 9413. Br J Cancer 76, 90–92 (1997). https://doi.org/10.1038/bjc.1997.341

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1997.341

This article is cited by

Search

Quick links